AstraZeneca, BMS Provide Grant for Diabetes Research Initiative - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AstraZeneca, BMS Provide Grant for Diabetes Research Initiative


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 2

AstraZeneca and Bristol-Myers Squibb reported that the companies’ US Diabetes Alliance is providing a three-year grant to the American Diabetes Association’s Pathway to Stop Diabetes program. The research initiative provides resources and support for a new generation of diabetes researchers and is designed to generate discoveries through collaboration and radical thinking.

The 2013 Pathway Awards will provide $1.6 million in support for five to seven years for the selected investigators and will fund research relevant to any diabetes type, diabetes-related disease state, or diabetes complication. Nominations included a range of disciplines, including medicine, biology, chemistry, engineering, physics, and mathematics.

Source: Bristol-Myers Squibb

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here